Journal
CANCER LETTERS
Volume 329, Issue 1, Pages 109-117Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.10.024
Keywords
Hepatocellular carcinoma; Radiotherapy; Sorafenib; In vitro; Xenograft model
Categories
Funding
- Ministry of Public Health, People's Republic of China [WSB1003]
- 211 Projects [EHF159102]
- 985 Projects [EZF159102]
- Ministry of Education, People's Republic of China
Ask authors/readers for more resources
The multikinase-inhibition action of sorafenib provides strong rationales for its combination use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined with irradiation on hepatocellular carcinoma (HCC). Sorafenib enhanced radiosensitivity of human HCC cell lines in a schedule-dependent manner. Sorafenib selectively inhibited radiation-induced activation of vascular endothelial growth factor receptor-2 (VEGFR2) and downstream extracellular signal-regulated kinase (ERK) pathway, induced DNA damage and suppressed DNA repair capacity, decreased radiation-activated NF-kappa B and increased radiation-induced apoptosis. In xenograft experiments, combination treatment produced marked tumor growth delay in both concurrent and sequential schedules. These results suggest that sorafenib could potentiate irradiation effect in HCC, which warrants further investigation for its potential clinical applications. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available